Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] Company Overview - Huaheng Biotechnology is a pioneer in synthetic biotechnology, focusing on the research, large-scale production, and commercialization of bio-based products [3] - The company has established a leading position in the industry through two decades of experience in biomanufacturing, with strong R&D capabilities and mature mass production capabilities [3] Market Position - According to Frost & Sullivan, Huaheng is one of the most comprehensive companies in the commercial application of bio-based products through synthetic biotechnology [3] - The company is the first globally to industrialize the anaerobic fermentation of a series of amino acids, including L-Alanine and L-Valine, and holds the largest market share for these products as of 2024 [3] Client Relationships - As of June 30, 2025, the company has established stable long-term partnerships with over 768 clients across 85 countries in major markets including Asia, Europe, and America [4] Product Portfolio - The main bio-based products include amino acids (primarily alanine series, L-Valine, tryptophan, arginine), vitamins (D-Calcium Pantothenate, D-Pantothenol, inositol), and other bio-based products [4] - The products are widely used in various industries such as animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition [4] Manufacturing Technology - The company employs two green manufacturing technology platforms: fermentation and enzyme catalysis, focusing on microbial cell factories and enzyme-based production processes [4] - This technology aims to replace traditional chemical synthesis with renewable biological resources, reducing pollution and energy consumption while minimizing carbon footprints [4] Market Growth - The global bio-based products market is projected to grow from USD 22.8 billion in 2020 to USD 42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6% [5] - The market is expected to further increase to USD 80.1 billion by 2030 and USD 109.1 billion by 2035, with a CAGR of 11.3% from 2024 to 2030 and 6.4% from 2030 to 2035 [5] Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion respectively [5] - The corresponding profits for the same periods were approximately RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5][6]

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1]. Company Overview - Huaheng Biotechnology is a pioneer in synthetic biology, focusing on the research, large-scale production, and commercialization of bio-based products through biomanufacturing technology [3]. - The company has established an industry-leading position in research and development, technology innovation, and mass production capabilities over the past twenty years in the biomanufacturing field [3]. - According to Frost & Sullivan, Huaheng is one of the most comprehensive companies globally in commercializing bio-based products through synthetic biology [3]. Product Portfolio - The company's bio-based products include amino acids (mainly L-alanine and L-valine), vitamins (such as D-calcium pantothenate and D-panthenol), and other bio-based products like 1,3-propanediol and succinic acid [4]. - These products are widely used across various industries, including animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition [4]. - Huaheng employs fermentation and enzyme catalysis as its two main green manufacturing technology platforms, focusing on microbial cell factories and enzyme-based production processes [4]. Market Potential - The global bio-based products market is projected to grow from USD 22.8 billion in 2020 to USD 42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6% [5]. - The market is expected to further increase to USD 80.1 billion by 2030 and USD 109.1 billion by 2035, with CAGRs of 11.3% from 2024 to 2030 and 6.4% from 2030 to 2035 [5]. - Companies with green manufacturing capabilities, large-scale production technologies, and collaborative advantages in the supply chain are anticipated to experience unprecedented growth opportunities in this context [5]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion, respectively [5]. - The corresponding profits for the same periods were about RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5]. - The gross profit margins for these years were 38.7%, 40.4%, 24.8%, and 23.5%, respectively, indicating fluctuations in profitability [7].